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VetCAST is the EUCAST sub-committee for Veterinary Antimicrobial Susceptibility
Testing. Its remit is to define clinical breakpoints (CBPs) for antimicrobial drugs (AMDs)
used in veterinary medicine in Europe. This position paper outlines the procedures and
reviews scientific options to solve challenges for the determination of specific CBPs for
animal species, drug substances and disease conditions. VetCAST will adopt EUCAST
approaches: the initial step will be data assessment; then procedures for decisions on
the CBP; and finally the release of recommendations for CBP implementation. The
principal challenges anticipated by VetCAST are those associated with the differing
modalities of AMD administration, including mass medication, specific long-acting
product formulations or local administration. Specific challenges comprise mastitis
treatment in dairy cattle, the range of species and within species breed considerations
and several other variable factors not relevant to human medicine. Each CBP will be
based on consideration of: (i) an epidemiological cut-off value (ECOFF) – the highest
MIC that defines the upper end of the wild-type MIC distribution; (ii) a PK/PD breakpoint
obtained from pre-clinical pharmacokinetic data [this PK/PD break-point is the highest
possible MIC for which a given percentage of animals in the target population achieves
a critical value for the selected PK/PD index (fAUC/MIC or fT > MIC)] and (iii) when
possible, a clinical cut-off, that is the relationship between MIC and clinical cure. For the
latter, VetCAST acknowledges the paucity of such data in veterinary medicine. When
a CBP cannot be established, VetCAST will recommend use of ECOFF as surrogate.
For decision steps, VetCAST will follow EUCAST procedures involving transparency,
consensus and independence. VetCAST will ensure freely available dissemination of
information, concerning standards, guidelines, ECOFF, PK/PD breakpoints, CBPs and
other relevant information for AST implementation. Finally, after establishing a CBP,
VetCAST will promulgate expert comments and/or recommendations associated with
CBPs to facilitate their sound implementation in a clinical setting.
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INTRODUCTION
There is increasing concern on the public health and animal
welfare consequences of antimicrobial resistance (AMR)
in bacteria from animal sources. The appropriate use of
antimicrobial drugs (AMDs) in veterinary medicine is one of the
key areas of European Union (EU) policy objectives to combat
AMR. Various initiatives have been taken by many national,
European and international bodies to promote prudent use of
AMDs (European Platform for Responsible Use of Medicines
in Animals, 2008; European Commission, 2011; Federation
of Veterinarians of Europe, 2012; European Food Safety
Authority, 2014; European Medicines Agency, 2015; World
Health Organisation, 2015; World Organisation for Animal
Health, 2016).
The importance of bacterial diagnostics and Antimicrobial
Susceptibility Testing (AST) as the basis for a rational choice
of an antimicrobial to treat an infection has been advocated in
numerous international and national guidelines and publications
(Federation of Veterinarians of Europe, 2012; European
Medicines Agency, 2015; World Health Organisation, 2015;
World Organisation for Animal Health, 2016), and by the
European Committee on AST – EUCAST1. Therefore, there is
an urgent need to achieve, in the EU, reliable interpretive criteria
for AST, which are harmonized and evidence-based. This will
ensure optimized and controlled AMD prescribing and use.
Currently, only one body, the Clinical Laboratory Standards
Institute (CLSI), an internationally recognized non-government
organization, with its veterinary sub-committee VAST, has
pioneered AST for veterinary medicine. As science is universal,
several procedures described in this paper are also inevitably
covered by CLSI/VAST documents, procedures and standards.
The CLSI methods are described in a series of commercial
documents (VET01, VET02, ..). These are not freely available
in the public domain, but are available to purchase by CLSI
customers at https://clsi.org/standards/products/veterinary-
medicine/documents/. In contrast, all VetCAST documents
will be freely available as required by general EUCAST
policy.
In 2015, VetCAST (Veterinary Committee on AST)
was established as a subcommittee of EUCAST (European
Committee on AST). VetCAST aims to advise on all aspects
of AST for bacterial pathogens of animal origin and animal
bacteria with zoonotic potential. An important consideration
is standardization of methodology for AST; this is essential
to ensure reproducibility of data between laboratories and
therefore the valid use of these data to estimate the prevalence
of resistance (Franklin et al., 2001). Equally important is the
application of inappropriate interpretative criteria to report
AST results. If such criteria are inappropriate the test will
be of limited or no value for the prescriber, even when the
laboratory methodology is standardized and reliable. This is
the case when no domestic animal species-specific veterinary
interpretative criteria, i.e., Clinical Breakpoints (CBPs), are
available.
1http://www.eucast.org
Comprehensive reviews on setting CBPs for human medicine
have been published (Turnidge and Paterson, 2007; Dalhoff et al.,
2009; Mouton, 2014), and other reviews have considered their
application in veterinary medicine (Constable and Morin, 2002;
Apley, 2003; Bywater et al., 2006; Schwarz et al., 2008; Lubbers
and Turnidge, 2015). The CLSI/VAST documents, notably the
VET01 and VET02 documents cover this topic (Clinical and
Laboratory Standards Institute, 2008, 2013). The objective of this
manuscript is to describe the procedures used by VetCAST to
define CBPs; these procedures will be within the format adopted
by EUCAST (see EUCAST SOP 1.2, 2016), but with emphasis
on considerations appropriate to veterinary medicine. This
procedure incorporates the EUCAST science-based, transparent
system for definition of CBPs.
GENERAL CONSIDERATIONS
Antimicrobial Susceptibility Testing is considered as one of the
most important factors governing the selection of antimicrobials
for clinical veterinary use (De Briyne et al., 2013). The primary
objective of AST in animal healthcare is selection of the most
appropriate antibiotic for the welfare interests of the animal to
be treated. A second important objective of AST is to ensure
good veterinary treatment practices, which take into account
public health hazards. A third objective is the provision of
good epidemiological AST surveillance data. In this respect,
AST was shown to be the most sensitive tool for detecting
the emergence of new resistance mechanisms (Mather et al.,
2016).
In veterinary medicine, as in human medicine, it is commonly
accepted that AST data predict the clinical outcome of AMD
treatment. In human medicine, however, it has been reported
that AST may sometimes fail to provide an accurate prediction
of clinical outcome (Doern and Brecher, 2011). Likewise, in
veterinary medicine, AST results may not always provide an
accurate prediction of clinical outcome. An example of poor
predictive value is AST for topical (intra-mammary) AMD
administration in mastitis therapy in cattle (Constable and
Morin, 2003; Barlow, 2011). One objective of VetCAST is to
provide evidence for the predictive value of AST, in terms of both
animal and public health.
Many factors account for the fact that AST and the Minimum
Inhibitory Concentration (MIC), determined in vitro using
standardized methodology, cannot reflect all aspects of complex
in vivo clinical circumstances. These factors were recently
reviewed by Martinez et al. (2013). The most important concern
for AST arises when no animal species- and infection-specific
veterinary CBPs are available; this may lead to the use of
inappropriate drugs or doses, potentially resulting in treatment
failure and, unintentionally, selection of antimicrobial resistance.
Therefore, the first remit of VetCAST is to develop and
implement animal species specific CBPs to ensure the provision
of scientifically driven and clinically relevant information
to antimicrobial stewardship programs (see Table 1 for the
definition of the main terms, abbreviation and acronyms used in
this paper).
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TABLE 1 | Definition of the main terms, abbreviation and acronyms used in this paper.
AMD Antimicrobial drug
AST Antimicrobial Susceptibility Testing
AUC Area under plasma concentration-time curve
AUC/MIC A PK/PD index; defined as the area under the concentration–time curve at steady-state over 24 h unless otherwise stated.
CART analysis Classification and Regression Tree Analysis
CBP Clinical Breakpoint; the values of MIC (mg/L) selected by an ad hoc committee to be used by testing laboratories to qualitatively report the
results of AST as Susceptible (S), Intermediate (I), or Resistant (R). Not to be confused with cut-offs.
CLSI The Clinical and Laboratory Standards Institute
CLSI/VAST Sub-committee of CLSI dealing with the susceptibility testing of veterinary pathogens and determination of veterinary CBP
Cmax/MIC A PK/PD index; the peak plasma concentration divided by MIC
CO A threshold value for MICs to separate two entities or targets
COCL Term not used by EUCAST; for CLSI, Clinical cut-off is the MIC value for which probability-of-cure can be achieved with a routine dosage
regimen in a given percentage of animals
EARS-Net European Antimicrobial Resistance Surveillance Network
ECDC European Center for Disease prevention and Control
ECOFF Epidemiological (bacteriological) cut-off
EFSA European Food Safety Authority
EMA European Medicines Agency
ESCMID European Society of Clinical Microbiology and Infectious Diseases
EU European Union
EUCAST European Committee on Antimicrobial Susceptibility Testing
FAO Food and Agriculture Organization (part of UN)
FDA Food and Drug Administration
MCS Monte Carlo simulation; Monte Carlo methods are a class of computational algorithms that use repeated random sampling to obtain numerical
results. In the context of AMDs, MCS is a tool for determining the probability of achieving a specific PK/PD index value defined as a PTA
MBC Minimum Bactericidal Concentration (mg/L)
MIC Minimum Inhibitory Concentration (mg/L)
OIE World Organization for Animal Health (retained OIE as its historical acronym)
PK Pharmacokinetics; drug disposition
PK/PD
breakpoint
Pharmacokinetic/Pharmacodynamic; the MIC value for which a targeted PK/PD index value can be achieved with a routine dosage regimen in a
given percentage of animals (usually 90%)
Prediction
interval
In statistical inference, specifically predictive inference, a prediction interval is an estimate of an interval in which future observations will fall, with
a certain probability, given what has already been observed.
PTA Probability of Target Achievement/Attainment (synonym of TAR). In Monte Carlo simulations, the probability that at least a specific value of a
pharmacodynamic index (e.g., 30% fT > MIC; fAUC/MIC of 100) is achieved at a certain (minimum inhibitory) concentration.
T > MIC A PK/PD index; the cumulative percentage of a 24 h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic
conditions unless otherwise stated
VetCAST Veterinary Committee for Antimicrobial Susceptibility Testing
VICH Veterinary International Conference on Harmonization; VICH is a trilateral (EU–Japan–United States) program aimed at harmonizing technical
requirements for veterinary product registration
WHO World Health Organization
THE REQUIREMENT FOR AND
CHALLENGES OF ESTABLISHING
SPECIES-SPECIFIC,
SUBSTANCE-SPECIFIC AND
DISEASE-SPECIFIC CLINICAL
BREAKPOINTS IN VETERINARY
MEDICINE
Clinical breakpoints are MIC values (expressed in mg/L), or
their surrogates such as zone diameters used by diagnostic
laboratories to categorize results of AST as Susceptible (S),
Intermediate (I), or Resistant (R). In veterinary diagnostics,
CBPs should be defined for each animal species, and for the
relevant bacterial target pathogens in each animal species.
Several specific veterinary features should be considered when
setting CBPs in veterinary medicine. For each animal species,
AMDs can be administered by various routes, including
parenteral administration (most commonly intramuscular
or subcutaneous routes) using formulations with short,
intermediate or long durations of action. Formulations for oral
administration range from single dose products to products
for administration in feed, including medicated feed, milk
replacer or drinking water. For these products and especially
for the oral route, bioavailability can be very variable, because
absorption rate and extent depend on both individual and group
animal behaviors. The consequence is large inter-individual
differences in pharmacokinetic profiles, which affect markedly
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the systemic exposure to AMDs and hence therapeutic outcome.
Some modalities of AMD administration are specific to
veterinary medicine; an important example is intra-mammary
administration in dairy cattle. For this route, not only is there
no equivalent human CBP, there is no conceptual framework
on how to develop a CBP, based on milk concentration in
the udder after local intra-mammary administration. All
these factors must be taken into consideration when defining
CBPs.
A further challenge is posed by within-species differences
in drug disposition (Toutain et al., 2010) and response,
e.g., pre-ruminant vs. ruminant calves vs. adult ruminants
(Martinez and Modric, 2010; Modric and Martinez,
2011). In addition, domestic animal species have evolved
into unique breeds with distinguishable characteristics,
deriving from genetic selection; this is particularly apparent
for dogs but also applies to poultry breeds and other
species. When feasible, VetCAST will take into account
the pharmacokinetic differences arising from intra-species
genetic and other variations. The consequence may be that
several CBPs will be defined for an AMD for a given animal
species.
The practice of selecting a single AMD to represent
all agents in the same pharmacological class, and hence
proposing pharmacological class CBPs, will need careful
consideration. For individual drugs within classes, both potency
and pharmacokinetics may vary widely and this in turn influences
the selected dosage regimen and CBP.
ESTABLISHING CLINICAL
BREAKPOINTS BY VetCAST
Based on the EUCAST SOP 1.2 (EUCAST SOP 1.2, 2016),
VetCAST will establish a formal and transparent approach for
the development and determination of CBPs. The rationale
underlying this approach is that the selection of a CBP by
VetCAST may impact the possible use, misuse or overuse of some
drugs.
The process for establishing CBPs by VetCAST will involve
three principal stages: a first scientific step involving assessment
of available data; second, a formal procedure for decision taking
on the CBP; and finally the recommendations for implementation
and use of the CBP (Figure 1).
The scientific assessment to establish a new CBP comprises
direct or indirect determination of two or three critical MICs.
These can be viewed operationally as MIC cut-off values
needed to assist the selection of the CBP (Figure 2): (i) an
epidemiological cut-off value (ECOFF), described by EUCAST
as the ECOFF (ii) a MIC to define a PK/PD cut-off, named
by EUCAST as the PK/PD breakpoint, and (iii) specifically in
veterinary medicine a MIC cut-off related to clinical outcomes,
the ‘clinical cut-off value.’ The clinical cut-off is not currently
described or used by EUCAST in human medicine. The
comparative richness of the data generated in human PK/PD
and clinical studies obviates the need for such a cut-off.
However, it is assessed indirectly when setting CBPs for human
pathogens because the value of the PK/PD index target that is
determined in clinical studies depends on the MIC collected
in individual patients. In veterinary medicine, such data are
rather scarce or non-existent, and this creates a need to examine
MIC vs. clinical outcome data directly. VetCAST will need to
explore some innovative approaches to integrate clinical data,
including the clinical cut-off, into the conceptual framework
of PK/PD vs. clinical outcome relationship. The CBP is the
final MIC value determined by considering all three cut-offs
together.
The scientific assessment of the data file required to establish
a CBP will involve input from all stakeholders, but especially
the veterinary pharmaceutical industry, which could provide raw
data with or without a preliminary analysis (e.g., a population
pharmacokinetic analysis to derive a PK/PD breakpoint).
VetCAST will issue a guideline on methods and standards for
collecting, archiving, handling and analyzing pharmacokinetic
data, and general guidelines for handling MIC distribution
data and determining ECOFFs will be published soon by
VetCAST on the EUCAST website. These two guidelines will
guarantee the quality of collected data, and a full transparency of
procedures in VetCAST’s determination of the three critical MIC
cut-offs.
After completion of the scientific assessment, the next stage
will be that of CBP selection. The CBP will be determined by
taking into account the previously established ECOFFs, PK/PD
breakpoints and clinical cut-offs.
This second step requires independence from all stakeholders
(public and private), and VetCAST members will decide CBPs
by consensus as done by EUCAST. When determined, CBPs
will be released as recommended MICs (mg/L), and a publically
available rationale document will be issued to explain and
justify the numerical values selected. The values of the ECOFFs,
PK/PD breakpoints and clinical cut-offs will also be available
publicly.
The final step involves the public release of information
(except that protected by confidentiality agreements) and issuing
of expert rules, as currently undertaken by EUCAST (Leclercq
et al., 2013).
For VetCAST, as currently is the case for EUCAST, the
veterinary pharmaceutical industry will be a partner and will have
an active consultative role, but will not have a financial role or
participate in decision-making, as is the case for the CLSI/VAST
sub-committee.
REPORTING TEST RESULTS
It is well established that a clinically relevant microbiology
report should constitute an integral part of any infectious disease
management program (Cunney and Smyth, 2000; Guardabassi
and Prescott, 2015). To assist clinical microbiologists in
preparing their report, VetCAST will provide ad hoc
guidance documents for interpretation of ASTs. This will
ensure the adequate and contextually correct interpretation
of AST results in the light of the animal’s local or regional
circumstances.
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FIGURE 1 | The successive steps in the process for establishing and implementing Clinical Breakpoints (CBPs) by VetCAST will follow three steps. The scientific
assessment is a scientifically based process comprising determination of two critical MICs associated to ECOFF and PK/PD breakpoint and of clinically collected
surrogates (MIC, AUC24h/MIC. . .) able to predict clinical outcomes. The second step is decision (provisional for review or final for implementation) of a CBP based
upon the different pieces of information determined at the previous step. This second step requires independence from all stakeholders. The final step involves
communication, and includes the interactive exchange of information on standards, expert comments, guidelines, SOPs, ECOFF, PK/PD breakpoint, the CBP and
any matter relating to susceptibility testing between VetCAST and its stakeholders.
EPIDEMIOLOGICAL CUT-OFF VALUES
(ECOFF)
For a given microbial species and agent, the ECOFF is the highest
MIC for organisms devoid of phenotypically detectable acquired
resistance mechanisms. It defines the upper end of the wild-
type MIC distribution (Figure 3). ECOFFs allow detection of
resistance to AMDs as a biological phenomenon. This may or
may not be clinically significant but may nevertheless constitute
an early warning of acquired resistance. ECOFFs are useful in
situations where CBPs have not yet been defined, as with some
topical or local agents (e.g., intra-mammary or gastro-intestinal
products) or where very different breakpoints may be appropriate
for different animal breeds within a given species, preventing the
selection of a single CBP.
Epidemiological cut-offs for a given bacterial species are
not affected by sampling time, source (human, animal, and
environmental) and geographical origin and are therefore
biological parameters. A CBP can never be lower than the
ECOFF (see rule 10.2 of the SOP 1.2 (European Committee on
Antimicrobial Susceptibility Testing, 2013) to prevent artificially
classifying part of the wild-type population as being resistant.
In order to define an ECOFF, MIC distributions for a given
bacterial species from different epidemiological and clinical
sources are combined. The proportion of wild-type relative to
non-wild-type may change but the boundary separating them
does not. The criteria for MIC distribution data sets acceptable
for ECOFF estimation are defined by EUCAST. In summary, a
minimal total number of 100 MIC values in the putative wild-type
population for each bacterial species, originating from at least five
accepted MIC data sets, are required to define an ECOFF.
Epidemiological cut-off values are not only used for CPB
determination but also for surveillance programs, when detection
of acquired resistance mechanisms is relevant.
The numbers of MIC distributions for veterinary pathogens
are increasing and are available on the EUCAST website.
VetCAST presently has a library of more than 25,000 individual
MIC results. Stakeholders are encouraged to send their in-house
data for aggregation, after review by VetCAST, with the already
published MICs [for details see (Kahlmeter, 2014)].
THE PK/PD BREAKPOINT
In humans, the PK/PD breakpoint set by EUCAST is generally
taken as the highest MIC for which a selected PK/PD
index can be achieved in the target population, given the
standard dosing regimes and taking into account the lower
95–99% prediction intervals for the population (Mouton
et al., 2012). For veterinary medicine in the EU, reference to
PK/PD concepts was first introduced in 2016 by EMA/CVMP
in its latest guidance on the demonstration of efficacy
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FIGURE 2 | Clinical breakpoints (CBP) are the values of the MIC (mg/L) selected by an ad hoc committee to be used by testing laboratories to qualitatively report the
results of AST as Susceptible (S), Intermediate (I), or Resistant (R). CBPs are determined by taking into account the ECOFF, the PK/PD breakpoint and the clinical
cut-off when available. CBP is established also by taking into account any aspects (scientific or not) that should be considered to ensure harmonization between
countries.
FIGURE 3 | The epidemiological cut-off (ECOFF) of amoxicillin for Escherichia coli; ECOFF is the MIC (8 µg/mL) that best separates the two sub-populations of the
observed MICs (from 0.25 to 256 µg/mL) distribution, i.e., the wild-type population and of the non-wild-type population. ECOFF is a parameter that can be
determined using simple visual inspection in the case of a clear bimodal distribution (as here) or by statistical techniques when greater certainty of the estimation is
required (EUCAST raw data).
of antimicrobial substances, although only for pre-clinical
investigation (European Medicines Agency, 2016). Currently,
no robust clinical data exist for veterinary medicinal products
to support any PK/PD breakpoint. Because of this, a PK/PD
breakpoint for veterinary medicine can only be established
after exploring a range of possible (not probable) MICs, within
which a clinical cure can be expected from application of
generic pre-clinical and clinical PK/PD principles. In others
words, the PK/PD breakpoint, as understood by EUCAST,
will be rather viewed for VetCAST as a PK/PD cut-off,
i.e., VetCAST will compute a series of Probability of Target
Attainments or PTA (vide infra for explanation of PTA) from
plasma concentration profiles and with no consideration of
clinical data. This is also the same procedure adopted by
CLSI/VAST under the name of PDCO (Clinical and Laboratory
Standards Institute, 2008). The range of MICs explored will
not be restricted to wild-type organisms, as a CBP can be
greater than an ECOFF with the currently recommended
dosage regimen. The PK/PD breakpoints may vary with
pathogen group, and both PK data and corresponding possible
MIC values are required to compute PK/PD breakpoints. In
veterinary medicine, some diseases can be associated with
several veterinary pathogens; examples are bovine respiratory
disease complex, swine respiratory disease etc. When several
causative agents are involved, that causative agent with the
highest possible MIC values will be used to compute the
PK/PD breakpoint (Figure 4). The following are required to
establish the PK/PD breakpoint: (i) the PK disposition of
the drug in the target animal species following a specific
route of administration, (ii) the target value of a selected
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FIGURE 4 | The three steps for the determination of a PK/PD breakpoint. The first step is to select one of the two PK/PD indices predictive of clinical efficacy, i.e.,
either the time for which plasma concentration remains above the MIC during the dosage interval (fT > MIC) or the ratio of area Under the plasma Concentration
curve over the MIC (fAUC/MIC); the second step is to determine the size of the selected index required to ensure clinical and bacteriological efficacy. The third step is
to determine, using Monte Carlo Simulation, the highest possible MIC for which a given percentage of animals in the target population (e.g., a prediction interval of
95%) is able to achieve the selected PK/PD index.
PK/PD index for bacterial pathogens of relevance predicting
a high likelihood of clinical/bacteriological cure, and (iii) the
usual range of MICs for a given pathogen for a specific
disease.
The PK/PD index selected to compute a PK/PD breakpoint
can be viewed as a surrogate of efficacy. Practically, the clinical
efficacy of AMDs can be correlated with one of the two following
PK/PD indices:
• The percentage of time that plasma concentration of
unbound drug remains above the MIC during the dosage
interval (f%T > MIC); this index is typically that seen with
beta-lactams, and is expressed as a percentage of the dosage
interval in the steady-state condition.
• The ratio of the Area Under the Plasma Concentration-
time curve for free drug to MIC (f AUC/MIC); this index
is seen with aminoglycosides, fluoroquinolones, macrolides
and tetracyclines.
• It should be noted that the ratio of the maximum free plasma
concentration and MIC, f Cmax/MIC was historically seen
with aminoglycosides but is now losing favor.
• The italic f indicates that these PK/PD indices should be
related to the free (unbound to plasma protein) AMD
plasma concentration, because only the free AMD has
antibacterial activity. Many reviews (Hyatt et al., 1995;
Ambrose et al., 2007; Craig, 2014b) have explained the
origin and usefulness of these indices, including their
application in veterinary medicine (Toutain, 2002; Toutain
et al., 2002; McKellar et al., 2004; Lees et al., 2006; Papich,
2014; Ahmad et al., 2016).
After selecting the index appropriate to the AMD, the
numerical target value to be achieved under steady-state
conditions (for multiple dose administrations) to predict clinical
efficacy must be established. In veterinary medicine, this has
historically been done either by using an experimental in vitro
system (e.g., time-kill curves) or in vivo studies in the target
species. However, the availability of in vivo data for this purpose
is rare. The determination of the target value of the PK/PD index
for valnemulin in poultry using an intratracheal Mycoplasma
gallisepticum infection model (Xiao et al., 2015) is an example.
When there are no specific veterinary data, a default value of the
predictive index is selected from human medicine. The rationale
for using values from human medicine is that they are frequently
derived from studies conducted in animal disease models (Craig,
2014a).
Target values of these indices indicate the systemic (in vivo)
exposure, normalized by MIC, required against each pathogenic
bacterial species; the target value itself does not depend on animal
characteristics, thus conferring on them a generic validity across
animal species. PK data are required only to define the specific
doses required to achieve the targeted index value. For example,
for beta-lactams, a typical target value for f T > MIC of 25–40%
of the dosage interval for Gram-positive pathogens and 40–50%
Frontiers in Microbiology | www.frontiersin.org 7 December 2017 | Volume 8 | Article 2344
fmicb-08-02344 December 13, 2017 Time: 15:21 # 8
Toutain et al. Veterinary Clinical Breakpoints by VetCAST
for Gram-negative pathogens is associated with a high likelihood
of success both clinically in humans and in rodent models (Craig,
1998).
The final step in the development of PK/PD breakpoints
comprises the determination of the percentage of animals, in
the treated population, for a particular dosing regimen, likely to
attain the target value of the selected PK/PD index, across a range
of relevant MIC values. Statistically, the PK/PD breakpoint is
related to the notion of a prediction interval (PI). The appropriate
choice of percentile (for instance 90, 95, and 99%) has not yet
been decided at VetCAST, but VetCAST anticipates that, due to
the large inter-animal variability and the paucity of data, a very
wide prediction interval could have large consequences for the
establishment of a CBP.
The estimation of the PK/PD breakpoint requires firstly the
building of a population PK model to quantify typical PK
parameters and their between-subject variability. This population
model is used to generate in silico, by Monte Carlo simulation
(MCS), a large sample of plasma disposition curves (typically
5000). This virtual in silico population is then used to determine
the different percentages of animals for which the target
PK/PD value will be attained at different possible MICs. These
percentages are the Probability of Target Attainment or PTA
(also historically termed Target Attainment Rate or TAR). The
principles of this stochastic approach have been described in
human medicine for AMD (Ambrose and Grasela, 2000; Dudley
and Ambrose, 2000; Drusano et al., 2001) and implemented
recently in veterinary medicine for tulathromycin (Toutain et al.,
2016) and oxytetracycline (Lees et al., 2016) in calves and
amoxicillin in calves (Lees et al., 2015) and pigs (Rey et al.,
2014).
VetCAST will take into account several issues to derive
the PK/PD breakpoint. The first concerns PK data; these may
be raw data generated by several stakeholders (mainly the
pharmaceutical industry but also academic laboratories) or
alternatively published/reported PK parameters (AUC, Cmax,
Volume of distribution and terminal half-life) as determined for
some drugs by VAST/CLSI and by others (Schwarz et al., 2008;
Maaland et al., 2013). In absence of raw data, average parameter
values and their standard deviation will be considered even if
this approach is not ideal. However, VetCAST is aware that
accounting for inter-animal variability in veterinary medicine
will very likely decrease the numerical value of some PK/PD
breakpoints. This is illustrated by the decrease of a PK/PD
breakpoint by up to two dilutions for amoxicillin in pigs: using
average PK parameters MIC values of≤0.5 mg/L were considered
as “susceptible” for respiratory tract pathogens (Schwarz et al.,
2008), whereas (Rey et al., 2014) using MCS reported that a
PTA of only 10.5% was achieved at this MIC for an oral dose of
10 mg/kg twice daily (Rey, 2011).
The availability of individual animal PK data from several
sources for a given AMD would allow VetCAST to perform a
meta-analysis by aggregating raw PK data (see Li et al., 2015 for a
review on value of meta-analysis in veterinary medicine) or by
statistical aggregation of summary data of PK parameters and
their associated variances. This would be based on a VetCAST
guideline on pharmacokinetic data handling.
For a given drug, a population PK analysis using a non-linear
mixed effect model is the only acceptable way to measure, with
equity, i.e., in a well-balanced manner, available concentration
data and covariates. This approach allows documenting the
various sources of variability of both biological origin (e.g.,
breed, sex, age, and health status) and non-biological origin (e.g.,
study design, sampling times, tested doses, analytical techniques
and missing data). Most PK data in veterinary medicine are
generated pre-clinically in healthy animals. VetCAST anticipates
gaining access to information derived from the treated patient
population, as the new EMA guidelines may formally encourage
veterinary drug companies to perform targeted-population PK
investigations during clinical trials (European Medicines Agency,
2016). This will also improve evaluation of the correlation
between individual drug plasma concentrations and clinical
outcome.
The advantage of population PK is its ability to detect
and quantify differences between breeds, formulations or
any covariates that might impede the use of a single final
CBP for a given AMD and a given pathogen. This may
occur when the AMD is marketed under very different
formulations or modalities of administration. This applies to
AMDs administered both orally (in medicated food or drinking
water – collective treatment) and intramuscularly using long-
acting, depot formulations that are commonly used in veterinary
medicine. Amoxicillin use in pigs provides an example of this
difficulty (Rey et al., 2014), and VetCAST will prepare ad hoc
expert comments to address issues such as a large difference
of some dog breeds to other breeds or to the influence of the
gastrointestinal physiology (e.g., ruminant vs. pre-ruminant) that
may need to be considered in the selection of CBPs.
Another challenging situation, specific to veterinary medicine,
is the case of time-dependent AMDs for which f%T > MIC
is considered as the appropriate PK/PD index. This challenge
arises because the target value of this PK/PD index depends
on the shape of the plasma exposure curve which may differ
widely between the many modalities of AMD administration
encountered in veterinary medicine. As an example for oral
administration, the possibility of pulse dosing of AMDs
by gavage at pre-determined intervals, or alternatively the
administration of AMD incorporated in food or drinking water,
thus approximating a sustained oral infusion over the day, may
affect the possibility to select a single common final CBP. As
it is unrealistic to propose several CBPs for a single drug for
a given animal species, VetCAST will explore alternatives, in
particular the possible use of f AUC/MIC as a default index,
as it is not influenced by the actual shape of the disposition
curve. The objective is to explore the possible similarity of PTA
obtained when using AUC/MIC as the PK/PD index but not
using T>MIC for the multiple modalities of drug administration
and/or for different formulations that are frequently used in
veterinary medicine. It is well established that the three PK/PD
indices exhibit some co-linearity (Corvaisier et al., 1998); and
this has also been reported in veterinary medicine (Greko
et al., 2003). More importantly, it has been shown, using a
semi-mechanistic in silico model, that AUC/MIC is the most
appropriate index, when the terminal half-life is relatively long
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relative to the dosage interval, even for beta-lactams (Nielsen and
Friberg, 2013; Kristoffersson et al., 2016). Validation of AUC/MIC
as an index of efficacy to ensure not increasing the risk of
promoting antimicrobial resistance when T > MIC is a relevant
metric, would greatly facilitate the assessment of most long-acting
formulations.
The main difficulty for these long-acting formulations is to
define their actual duration of efficacy. In human medicine,
PK/PD values are obtained under steady-state conditions,
because most AMDs are administered on a daily basis using
multiple dosing treatment. For this modality of multiple doses,
the duration of action is implicitly the same as the duration
of treatment. For long-acting formulations, or for drugs with
a long terminal half-life, the common practice in veterinary
medicine is to administer a single dose. Consequently, estimation
of f AUC/MIC is complicated by the need to first determine
the duration of action of the product, and this information is
often lacking in the Summary of Product Characteristics dossiers.
The solution is to compute PK/PD index values for different
incremental time periods with steps of 24 h and to derive a
PK/PD breakpoint for each total duration of activity (0–24,
0–48, 0–72 h. . .). This approach implies a trade-off between the
target value of the PK/PD index and the claimed duration of
activity, and the final CBP will not only be dose-dependent, as in
human medicine, but also, for these types of drugs/formulations,
a function of the claimed duration of AMD activity. Therefore,
a formulation/substance for which a company wishes to claim a
long duration of action will ineluctably have a lower “average 24 h
PK/PD index value,” and ultimately a lower CBP. An example
of this approach has been recently published for tulathromycin,
a macrolide with a terminal half-life of 84 h in calves (Toutain
et al., 2016). As explained in the section on how VetCAST will
establish the CBPs, ECOFFs will be recommended in situations
where a single CBP cannot be firmly established, i.e., a single
CBP to cover the multiple modalities of AMD administration of
different formulations marketed in the EU.
THE CLINICAL CUT-OFF VALUE
The third piece of information to establish a CBP should
be directly related to clinical outcomes and requires specific
investigations during prospective clinical trials. At EUCAST what
is established in patients, who yielded bacterial clinical isolates
for MIC testing, is the value of the calculated PK/PD index
(e.g., AUC24h/MIC or T > MIC) that best discriminates between
clinical outcomes (e.g., cure vs. non-cure). Currently there is
no veterinary clinical example where such an exposure/effect
relationship has been demonstrated in a clinical setting.
Furthermore, such a relationship cannot be always readily
obtained. A retrospective analysis of 16 randomized clinical trials,
conducted to explore the relationship between in vitro MICs
of tilmicosin against Mannheimia haemolytica and Pasteurella
multocida and the outcome of tilmicosin treatment, showed a
tendency for greater treatment success against infections with
M. haemolytica isolates classified as susceptible compared to
those categorized as either intermediate or resistant. However,
this difference was not statistically significant (P = 0.08)
(McClary et al., 2011). It is in practice very difficult to distinguish
between curable vs. non-curable sub-populations based solely on
a MIC, especially when an ad hoc trial has not been designed
for this purpose. This is because AST only measures the in vitro
interaction between pathogen and drug. It does not take into
consideration disease severity and pathogen load in the biophase,
immunological response to the disease, secondary mechanisms
of action of AMDs, or the numerous other clinical factors (such
as co-medications, timing of treatment initiation relative to
development of the disease and individual drug disposition) that
may influence treatment outcome (Turnidge and Paterson, 2007;
Martinez et al., 2013).
Clinical correlation with AST (MIC), even when it does exist,
may be difficult to establish, because most clinical trials do not
include enough animals infected with non-wild-type organisms
(high MIC). Furthermore, there are often insufficient cases of
clinical failure, irrespective of the MIC, because clinical trials are
planned to provide evidence of efficacy rather than to quantify
lack of efficacy.
Despite these complications, VetCAST will consider clinical
data. As EMA requires collection of bacteriological samples
during clinical trials, unexplored proprietary databases in
veterinary medicine, from which a clinically significant MIC
could be reliably determined, are likely to exist. In addition,
EMA is now encouraging the use of population PK for veterinary
medicine and it can be anticipated that VetCAST would also
explore as for human medicine the relationship between some
PK/PD index as AUC/MIC and the treatment outcome, which
can be either clinical or bacteriological cure. It would be possible
to apply classification and regression tree analysis (CART) to
identify the clinical cut-off, if appropriate data (AUC/MIC,
T > MIC but also AUC/MBC, Dose/MIC. . .) vs. outcomes are
rich.
Irrespective of the clinical predictive variable of clinical
outcomes considered for statistical analysis (MIC, AUC/MIC. . .),
clinical trials should be conducted according to acknowledged
guidelines (FDA, EMA, and VICH) in order to be considered for
such an assessment. Furthermore clinical isolates from these trials
should be subjected to a subsequent MIC determination.
DATA ASSESSMENT FOR LOCAL AMD
ADMINISTRATION: THE CASE OF
MASTITIS IN DAIRY CATTLE
A challenging issue for AMD use in veterinary medicine
concerns local administration, notably for mastitis treatment
in dairy cattle. The potential advantage is that high local
drug concentrations and exposures may be achieved at the
site of infection with a relatively low dose of AMD, thus
minimizing unwanted systemic side-effects and ingestible tissue
residues (Gruet et al., 2001). As the milk concentration can be
very high and not in parallel with the plasma concentration
profile, it is logical to hypothesize that the concentration
in milk is the most appropriate for evaluating infection site
exposure.
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Veterinary-specific CBPs for intra-mammary AMD
administration have been established by the CLSI/VAST
committee and include a penicillin/novobiocin combination,
ceftiofur, pirlimycin, and cefoperazone (Clinical and
Laboratory Standards Institute, 2007). CLSI/VAST adopted
the straightforward approach of evaluating the time above which
the milk concentration is above a critical MIC (T > MIC) with a
recommended dosage regimen. For example, for cefoperazone,
it was concluded that a concentration of 2 mg/kg milk could
be achieved, after regular dosing, for the entire 24 h dosing
interval with the 250 mg product and for approximately 80%
of the 48 h dosing interval with the 100 mg product (Fessler
et al., 2011). Consequently, a MIC breakpoint of 2 mg/L was
selected for the category “susceptible” for all bovine mastitis
pathogens. However, the udder cannot be simply considered
as “a well-stirred milk pot,” and several conceptual, major PK
and PD issues will be examined by VetCAST before specific
recommendations for CBP determination can be established for
this and other local routes of administration. As stated above,
ECOFFs will be recommended in situations like this where CBPs
cannot be firmly established.
THE ESTABLISHMENT OF CLINICAL
BREAKPOINTS BY THE VetCAST
STEERING COMMITTEE
The CBP will be determined by the VetCAST steering committee
after completion of the scientific assessment. As explained
above, members of this group will not be representative of any
national breakpoint committee but are acknowledged as intuitu
personae experts. As stated by Turnidge and Paterson (2007)
it is essential that the membership of any breakpoint-setting
committee includes persons to encompass a range of skills; and
this will include for VetCAST scientists in the fields of clinical
microbiology, epidemiology, infectious diseases, pharmacology,
clinicians and regulatory affairs. Declarations, confirming the
absence of any conflict of interest, for those involved in any
step of the establishment of a CBP will be updated annually.
At VetCAST, decision taking will be carried out according
to the EUCAST procedure through a consensus process. The
principal reason for adopting consensus is that EUCAST is an EU
consensus-driven organization.
Operationally, CBPs will be established by VetCAST from
the MIC cut-off values derived from (i) the ECOFF (ii) the
PK/PD breakpoint and when available (iii) the clinical cut-off.
Alternative to the latter is to consider some metrics predictive of
clinical outcome (Dose/MIC, AUC/MIC. . .) as computed during
the scientific assessment step. There is no generally accepted
formula or mechanism for combining these different pieces of
information into a single CBP to define the Susceptible category.
Decisions in the final analysis are a matter of judgment by
experts drawn from several disciplines and based on reflective
consideration of all available information.
Historically, most emphasis in veterinary medicine has
been given to epidemiological and clinical considerations and
for CLSI/VAST, the so-called PK/PD cut-off (named COPD)
is a relatively recent innovation. PK/PD cut-off differs from
PK/PD breakpoint as understood by EUCAST by the fact that
a PK/PD cut-off is derived only from PK data without clinical
considerations. It is the VetCAST view that selecting a MIC
having a robust clinical meaning is challenging for a range of
reasons explained above. Therefore, VetCAST supports the
conclusion of Turnidge and Paterson (2007) that much of the
pivotal information is embedded in the PK/PD breakpoint.
This is because the PK/PD breakpoint is a hybrid value,
incorporating all three principal components (microbiological,
pharmacological, and clinical) predicting clinical efficacy.
Operationally, if the PK/PD breakpoint is below the ECOFF, it
probably means that the current dosage regimen for that AMD is
too low to treat the wild-type population. In this case, VetCAST
will not establish a CBP dividing the wild-type MIC distributions
(Arendrup et al., 2009). However, it should be emphasized that
VetCAST has no authority, at that level, to recommend a change
of dosage regimen. On the other hand, a CBP can be established
if the PK/PD breakpoint is greater than or equal to the ECOFF,
and, under these circumstances, clinical data, when available
should be considered to support the PK/PD breakpoint.
VetCAST COMMUNICATION AND
CONSULTATION
For VetCAST, dissemination of information, concerning
standards, guidelines, SOPs, ECOFF, PK/PD breakpoint, CBPs
and any additional issues relating to susceptibility testing, will be
interactive with stakeholders. The latter include international and
national agencies, professional organizations, other committees
such as CLSI/VAST, prescribers, scientific news media, and
other interested groups. The VetCAST steering committee will
propose a tentative CBP based on data assessment for public
consultation. Stakeholders such as pharmaceutical companies
or any organizations may subsequently send comments to or
request meetings with the VetCAST Steering Committee. This
open communication will facilitate a possibility to take new
data into consideration, to provide further discussion or to seek
clarification of the VetCAST rationales for determining the
CBP.
In terms of communication, a crucial issue will be to explain
and communicate the fact that new or revised VetCAST CBPs
or ECOFFs can have many repercussions for microbiological
laboratories, similar to those reported by a focus group regarding
CLSI policy (Jenkins and Jerris, 2011). This includes the
development and validation of new laboratory methods and,
more importantly, the possibility of reporting as susceptible
those isolates that would be classified as resistant, based on
the previously employed breakpoint (or ECOFF), or conversely
reporting as resistant isolates previously classified as susceptible
when the CBP is decreased (see also Hombach et al., 2012;
Heil and Johnson, 2016). For similar reasons, the prevalence
of resistance, assessed from aggregated AST results at regional,
national or international levels, might be substantially altered,
especially when a CBP, rather than ECOFF, is used to report
resistance.
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The independent status of VetCAST, when it expresses general
views to all groups concerned with AMD usage and dosage, is
crucial.
VetCAST will communicate via the EUCAST website and
regularly consult with stakeholders. All relevant material will
be freely available to any testing laboratory, including those
in resource-poor settings, to provide an updated and readily
available reference for interpreting pathogen susceptibilities
to AMDs.
EXPERT COMMENTS FOR
STAKEHOLDERS
An important item of communication, after establishing a CBP, is
to promulgate a set of expert comments and/or recommendations
associated with the new VetCAST CBP. Expert rules are intended
to assist clinical microbiologists in the routine interpretation
of AST data and to suggest the most appropriate actions to
be taken in response to specific AST results, i.e., not to be
restricted to the simple reporting of S, I, or R. As for EUCAST,
expert rules (Leclercq et al., 2013) for VetCAST will include
recommendations on reporting (including the suppression of
results when possibly misleading) and editing of results on the
basis of an inferred resistance mechanism, inferring susceptibility
to other agents from reported results etc. For veterinary
medicine, a single CBP for each AMD is unlikely to cover all
clinical situations and other circumstances (local vs. systemic
administration, curative vs. metaphylaxis dosing, possible effect
of breed, formulations. . .). Therefore, these expert rules will
place data in perspective, based on microbiological and clinical
considerations, with warnings on the interpretation, relevance
and limitations of the VetCAST CBP. Further, they will advise
on additional tests that might be required. These expert rules will
be regularly updated and could be incorporated into the software
of susceptibility testing devices.
PASSIVE RESISTANCE SURVEILLANCE
AND CBPs
As indicated above, AST results can be aggregated at different
geographical levels within Europe, similar to that of the database
of the European Antimicrobial Resistance Surveillance Network
(EARS-Net). Passive surveillance is less expensive than other
surveillance strategies, and is the most effective approach for
detecting rare and potentially emerging resistance (Mather et al.,
2016).
For surveillance purposes especially if CBPs have not been
harmonized, the most relevant criterion is the ECOFF, which
separates the wild-type from the non-wild-type population,
and therefore does not differ between countries or over time.
Therefore, one of the priorities of VetCAST will be to collect
MICs of many isolates of interest to both animal and public
health, in order to establish science-based ECOFFs. This goal
could be shared with CLSI/VAST with the joint promotion of a
set of international ECOFFs.
CONCLUSION
To ensure the dominant role of AST as a phenotypic diagnostic
test for veterinary medicine, it is crucial to improve its accuracy
and predictive clinical value. VetCAST aims to do this by
definition of science-based interpretive criteria and CBPs based
on integration of microbiological in vitro potency with in vivo
pharmacological and clinical data as described in this position
paper. As part of this process, VetCAST will address complexing
issues that are specific for veterinary medicine, e.g., long-
acting formulations, in feed medication, frequent use of topical
formulations, and animal species and breed-specific differences
in pharmacokinetic drug profiles.
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